Medication info
Glucitag Tablet 50 mg (Sitagliptin Hydrochloride Hydrate)

Glucitag Tablet 50 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tablet
Manufacturer / importer
Kibs Biopharma Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablets
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202102831 · Approved 2021.03.31 · Insurance code 693202450

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, evaluation of renal function is recommended before starting treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Kibs Biopharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to assist patients with type 2 diabetes in controlling blood sugar levels in conjunction with dietary and exercise therapies. It can be used alone for initial treatment, and if blood sugar control is insufficient with monotherapy, it may be combined with other diabetes medications such as metformin. Additionally, when blood sugar control is inadequate with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin, this medication can be added to enhance therapeutic efficacy. This medication is also aimed at improving blood sugar control even when multiple medications are used together. Overall, this medication is utilized to effectively improve blood sugar levels in various treatment stages.

How to take

Adult dose

Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, evaluation of renal function is recommended before starting treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause severe allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and seek medical attention. Additionally, there is a risk of developing acute pancreatitis, a serious inflammation of the pancreas. If symptoms like abdominal pain or vomiting occur, visit a medical facility promptly. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, nor should it be used in cases of hypersensitivity to this medication or its components. Patients with impaired renal function may need dosage adjustments due to slower excretion of the drug, and regular kidney function monitoring is important. Hypoglycemia may occur during use of this medication, so especially when used together with insulin or sulfonylureas, it is important to frequently check blood sugar levels and take precautions against hypoglycemia. Severe joint pain or blistering skin conditions may develop, so if such symptoms appear, consult a doctor immediately. Use of this medication is not recommended during pregnancy or breastfeeding, and safety and efficacy have not been established for pediatric patients under 18 years of age. Elderly patients may experience decreased renal function, requiring dosage adjustments and monitoring. In case of overdose, seek medical attention immediately as this medication can be partially removed by dialysis. During use of this medication, side effects such as dyspepsia, headache, upper respiratory infections may occur, so symptoms should be monitored, and if anomalies arise, consult healthcare professionals.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 28 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disability-related arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air exposure, ideally at a temperature between 1 degree and 30 degrees Celsius. This will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablets

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.